An additional step was achieved on last October, with Japan granting the patent that protects O2L-001. After US, this is the second large geographic area of patent protection. This decision strengthens our development and our international strategy.
As a follow-up of our settlement with a new company settlement in Caen, Op2Lysis communicates in Ouest-France.
The article is available at the following address
One week of immersion in Boston, thanks to the NETVA program, coordinated by the Consulat de France in Boston, allowed us to benefit from the consulate network, as they introduced us into the biggested US ecosystem for Biotechs, including VCs, the local teams of Business France and of the French Tech Hub, preclinical CROs, and lawyers. We also met with renowned neurologists, emergency room physicians and neurosurgeons, as well as with neuroimaging specialists from Boston’s main hospitals (MGH, BU Hospital, Beth Israel). These early academic feedbacks were very encouraging on the potential of the therapeutic option that we develop.
This is the conclusion of a survey led by the French stroke foundation on 986 people in October 2017. The questionnaire, which is available on the web, shows that one out of three people do not dial the emergency telephone number when facingstroke symptoms.
As a reminder, STROKE requires FAST action
Question : Do you know about your blood pressure ?
90 % of the stroke events are related to ten modifiable risk factors. Prof. Serge Timsit, Neurologist and President of the « Société Française Neuro-Vasculaire (SFNV) » reports below.
We are proud to announce the grand opening of our R&D site in Caen, at the Cyceron Center, where the Op2Lysis technology was invented. We also took the opportunity to show the laboratory to Estelle Louet, our first employee, who should join the team by December 2017 to work with us while pursuing her doctoral studies for a PhD level.
As a result of a long and hard work, which was led over these last months and allowed a revision of the terms negotiated for the O2L-001 license, as well as gaining non-dilutive fundings (i-LAB and loans on trust) and numerous prizes and recognitions, Op2Lysis initiated its crowdfunding campaign on the WiSEED.com platform.
The objective of this fundraising is to fund the feasibility of the industrial production and formulation of O2L-001 over the next 12 months. At the end of this first period of our development program, we will have sufficient information on production, purification, and formulation to initiate the regulatory preclinical steps of O2L-001 development, with a compound able to liquefy an intracerebral hematoma with one single injection. Scale-up and preparation of the regulatory studies will require a second fundraising for 2019.
September 2017 – French-Flemish meeting with the FIT Agency in Leuven (BE)
Op2Lysis was in Leuven during the French-Flemish meetings, which were organized by Flanders Investment and Trade (FIT). Great meeting opportunities.
Prof. Denis Vivien was invited to attend ISTH (International Society on Thrombosis and Haemostasis) in Berlin (Germany) and present his lab’s experience on preclinical models of ischemic or hemorrhagic strokes. He also introduced STROKE@LLIANCE, a program that was launched to improve the translational progress of drug candidates towards clinical stage through mimicking at the preclinical lab stage the heterogeneity of early clinical phases.